SGLT2 inhibitors are associated with lower rates of death for patients with type 2 diabetes

Peter Sayer, Alison Bloomer, and Eve Batt report from the 77th annual Scientific Sessions of the American Diabetes Association (ADA).  The CVD-REAL study analysed the outcomes of 306,156 patients with type 2 diabetes from five different countries—the US, UK, Norway, Sweden and Denmark—who were treated with SGLT2- inhibitors. SGLT2 is a protein responsible for glucose regulation in the body. SGLT2 inhibitors reduce renal glucose reabsorption by causing excess blood glucose to be expelled through urine. Using data from clinical practice, researchers compared rates of heart failure (HF) and death in patients with and without prior cardiovascular disease (CVD) to HF rates in